US to no longer dis­trib­ute Eli Lil­ly’s bam­lanivimab alone due to coro­n­avirus vari­ants

The US gov­ern­ment and Eli Lil­ly agreed to halt all dis­tri­b­u­tion of the com­pa­ny’s Covid-19 mon­o­clon­al an­ti­body bam­lanivimab as of Wednes­day due to the “sus­tained in­crease” of coro­n­avirus vari­ants in the US.

All treat­ment de­liv­ery sites will con­tin­ue to be able to or­der Lil­ly’s com­bo Covid-19 treat­ment of bam­lanivimab and ete­se­vimab, to be ad­min­is­tered to­geth­er, or Re­gen­eron’s an­ti­body cock­tail, the as­sis­tant sec­re­tary for pre­pared­ness and re­sponse (AS­PR) and FDA said. Both of the treat­ments from Lil­ly and Re­gen­eron have proven to be use­ful among peo­ple who have Covid-19 but are not hos­pi­tal­ized.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER